Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects.
Park H, Kim CO, Kim M, Lim Y, Lee WY, Yoon S, Park MS. Park H, et al. Transl Clin Pharmacol. 2020 Sep;28(3):136-146. doi: 10.12793/tcp.2020.28.e16. Epub 2020 Sep 23. Transl Clin Pharmacol. 2020. PMID: 33062627 Free PMC article.
Group 1 received YH4808, amoxicillin, and clarithromycin as a novel triple regimen, while Group 2 received YH4808 and amoxicillin only, and Group 3 received esomeprazole, amoxicillin, and clarithromycin, as the standard triple regimen. ...However, the onset times of …
Group 1 received YH4808, amoxicillin, and clarithromycin as a novel triple regimen, while Group 2 received YH4808 and amoxicil …
Comparison of the pharmacokinetics and pharmacodynamics of YH4808 in healthy subjects for defining an appropriate dosing regimen.
Yoon S, Oh E, Park MS, Jang SB, Byun HM, Park H, Kim H, Kim CO. Yoon S, et al. Transl Clin Pharmacol. 2021 Sep;29(3):150-159. doi: 10.12793/tcp.2021.29.e15. Epub 2021 Sep 17. Transl Clin Pharmacol. 2021. PMID: 34621707 Free PMC article.
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. ...YH4808 exhibited potential for better pH control during the night in comparison to esomeprazole. ...
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. ...YH4808 exhibited potenti …
A population PK-PD model of YH4808, a novel P-CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808.
Chung TK, Lee HA, Lee KR, Jang SB, Yu KS, Lee H. Chung TK, et al. CPT Pharmacometrics Syst Pharmacol. 2022 Sep;11(9):1223-1233. doi: 10.1002/psp4.12839. Epub 2022 Jul 9. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35748058 Free PMC article.
In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of YH4808 were modeled in healthy male volunteers who received a single oral dose of YH4808 at 30, 50, 100, 200, 400, 600, and 800 mg or matching placebo and multiple once-daily oral doses of …
In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of YH4808 were modeled in healthy male volunteers who recei …
A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K(+)-competitive acid blocker.
Lee HA, Lee KR, Jang SB, Chung SY, Yu KS, Lee H. Lee HA, et al. Eur J Pharm Sci. 2019 Mar 15;130:1-10. doi: 10.1016/j.ejps.2019.01.009. Epub 2019 Jan 11. Eur J Pharm Sci. 2019. PMID: 30641142 Clinical Trial.
A physiologically-based pharmacokinetic (PBPK) model was developed for YH4808, a novel potassium-competitive acid blocker, using the SimCYP Simulator based on the physicochemical, in vitro preclinical and clinical data of YH4808. ...Overall, the PBPK model adequatel …
A physiologically-based pharmacokinetic (PBPK) model was developed for YH4808, a novel potassium-competitive acid blocker, using the …
Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects.
Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, Park H, Yoon S, Park MS, Hong T. Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28(1):55-65. doi: 10.12793/tcp.2020.28.e5. Epub 2020 Mar 31. Transl Clin Pharmacol. 2020. PMID: 32274381 Free PMC article.
YH4808 is a novel potassium-competitive acid blocker that was developed as a therapeutic agent for gastric acid-related diseases; it may replace proton pump inhibitors, which are widely used in combination with amoxicillin and clarithromycin for Helicobacter pylori eradica …
YH4808 is a novel potassium-competitive acid blocker that was developed as a therapeutic agent for gastric acid-related diseases; it …
An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.
Kim A, Yu BY, Dueker SR, Shin KH, Kim HS, Ahn H, Cho JY, Yu KS, Jang IJ, Lee H. Kim A, et al. Clin Pharmacol Ther. 2017 Sep;102(3):537-546. doi: 10.1002/cpt.672. Epub 2017 May 26. Clin Pharmacol Ther. 2017. PMID: 28214288
(14) C-labeled YH4808, a novel potassium-competitive acid blocker, was intravenously administered as a microtracer at 80 mug (11.8 kBq or 320 nCi) concomitantly with the nonradiolabeled oral drug at 200 mg to determine the absolute bioavailability and to assess the effect …
(14) C-labeled YH4808, a novel potassium-competitive acid blocker, was intravenously administered as a microtracer at 80 mug (11.8 kB …
Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.
Kim E, Kim A, Yi S, Kim YK, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S. Kim E, et al. Eur J Clin Pharmacol. 2018 Oct;74(10):1261-1272. doi: 10.1007/s00228-018-2502-9. Epub 2018 Jun 15. Eur J Clin Pharmacol. 2018. PMID: 29907887 Clinical Trial.
PURPOSE: YH4808 is a potassium-competitive acid blocker, developed for the treatment of acid-related disorders. Two clinical studies in healthy male subjects were conducted to evaluate the effect of food on the pharmacokinetics of YH4808. METHODS: The first study, a …
PURPOSE: YH4808 is a potassium-competitive acid blocker, developed for the treatment of acid-related disorders. Two clinical studies …
A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.
Yi S, Lee H, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS. Yi S, et al. Aliment Pharmacol Ther. 2017 Aug;46(3):337-346. doi: 10.1111/apt.14148. Epub 2017 May 21. Aliment Pharmacol Ther. 2017. PMID: 28543183 Clinical Trial.
A twice-daily regimen of YH4808 more effectively controlled intragastric pH at night than a once-daily regimen. ...YH4808 was well-tolerated at all doses administered. CONCLUSION: This study showed that YH4808 produced a rapid, sustained suppression of gastri …
A twice-daily regimen of YH4808 more effectively controlled intragastric pH at night than a once-daily regimen. ...YH4808 was …